Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Revenue of Exscientia plc (EXAI)
Revenue in 2023 (TTM): $20.08 M
According to Exscientia plc's latest financial reports the company's current revenue (TTM) is $20.08 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Exscientia plc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $20.08 M | $-7,324,000 | $-145,453,000 | $-162,088,000 | $-145,963,000 |
| 2022 | $26.82 M | $-5,950,924 | $-159,895,000 | $-138,338,591 | $-116,735,924 |
| 2021 | $20.32 M | $7.63 M | $-52,499,000 | $-41,687,394 | $-36,524,529 |
| 2020 | $13.18 M | $-6,206,304 | $-23,225,000 | $-33,224,307 | $-30,367,826 |
| 2019 | $11.94 M | $4.55 M | $-7,420,000 | $-10,547,018 | $-8,282,635 |